Revisiting: Drawing from a pen cartridge with a syringe: how the risk profile changes

Revisiting: Drawing from a pen cartridge with a syringe: how the risk profile changes Writing it up because I had to work it out twice and would rather nobody else did.

I have read the maintained page on this and I still have a gap, so I am asking rather than guessing.

Context: tirzepatide, 23 weeks in, currently at a dose I reached by the standard four-week steps. Everything below is my own record rather than anything a clinician told me.

The specific question is the one in the title. What I have already checked: the labelling summary on the relevant documentation page, the two most-linked topics in this subcategory, and my own notes from the last 6 weeks. What I could not find is whether the answer changes at higher doses or whether it is the same arithmetic throughout.

If the answer is "it depends", I would rather know what it depends on than be given a number.

Reusability: some pens are single-use (throw away after one injection). Others can be reused until empty. Confirm which type you have. Reusing a single-use pen is ineffective because the mechanism does not reset.

Coming back to the opening post, because the follow-up matters more than the original answer.

Visibility of the dose: some pens allow you to see the insulin remaining; others do not. Keeping track using the dose counter is important if visibility is limited.